BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Medtronic
Merck
Novartis
Express Scripts
Healthtrust
QuintilesIMS
Colorcon
Fish and Richardson
Federal Trade Commission

Generated: January 16, 2018

DrugPatentWatch Database Preview

ZANAFLEX Drug Profile

« Back to Dashboard

Which patents cover Zanaflex, and when can generic versions of Zanaflex launch?

Zanaflex is a drug marketed by Acorda and is included in two NDAs.

The generic ingredient in ZANAFLEX is tizanidine hydrochloride. There are eleven drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the tizanidine hydrochloride profile page.

US Patents and Regulatory Information for ZANAFLEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Acorda ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-001 Aug 29, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Acorda ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-002 Feb 4, 2000 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Acorda ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-002 Aug 29, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Acorda ZANAFLEX tizanidine hydrochloride CAPSULE;ORAL 021447-003 Aug 29, 2002 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Acorda ZANAFLEX tizanidine hydrochloride TABLET;ORAL 020397-001 Nov 27, 1996 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ZANAFLEX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 2 mg, 4 mg and 6 mg ➤ Subscribe 8/10/2007

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Julphar
Baxter
Chinese Patent Office
Federal Trade Commission
Fish and Richardson
McKesson
Chubb
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot